James Richard Porter Sells 30,000 Shares of Nuvalent (NASDAQ:NUVL) Stock

Nuvalent, Inc. (NASDAQ:NUVL) CEO James Richard Porter sold 30,000 shares of Nuvalent stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $88.53, for a total value of $2,655,900.00. Following the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $28,761,537.87. This represents a 8.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

James Richard Porter also recently made the following trade(s):

• On Monday, May 4th, James Richard Porter sold 30,000 shares of Nuvalent stock. The stock was sold at an average price of $101.69, for a total value of $3,050,700.00.
• On Monday, April 6th, James Richard Porter sold 30,000 shares of Nuvalent stock. The stock was sold at an average price of $103.77, for a total value of $3,113,100.00.

Nuvalent Stock Performance

Nuvalent stock traded up $0.10 during midday trading on Wednesday, reaching $123.35. 6,272,843 shares of the company were exchanged, compared to its average volume of 1,119,983. The company has a market capitalization of $9.74 billion, a price-to-earnings ratio of -20.35 and a beta of 1.15. The firm’s 50-day simple moving average is $102.91 and its 200-day simple moving average is $103.08. Nuvalent, Inc. has a 1 year low of $71.13 and a 1 year high of $123.62.

Nuvalent (NASDAQ:NUVL) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.04). During the same period in the previous year, the firm posted ($1.18) earnings per share. On average, analysts forecast that Nuvalent, Inc. will post -5.74 EPS for the current fiscal year.

Analyst Ratings Changes

NUVL has been the subject of several recent analyst reports. Wells Fargo & Company restated an “equal weight” rating and issued a $124.00 price target (up from $116.00) on shares of Nuvalent in a report on Tuesday. Lifesci Capital cut Nuvalent from an “outperform” rating to a “hold” rating and set a $124.00 price target for the company. in a report on Tuesday. Piper Sandler cut Nuvalent from an “overweight” rating to a “neutral” rating and set a $124.00 price target for the company. in a report on Tuesday. Robert W. Baird set a $122.85 price target on Nuvalent in a report on Tuesday. Finally, UBS Group cut Nuvalent from a “buy” rating to a “neutral” rating and lowered their price target for the company from $138.00 to $124.00 in a report on Wednesday. Eight equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $131.15.

Hedge Funds Weigh In On Nuvalent

Several hedge funds and other institutional investors have recently modified their holdings of NUVL. GAMMA Investing LLC lifted its stake in shares of Nuvalent by 47.6% in the 4th quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after purchasing an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Nuvalent by 141.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock valued at $34,000 after purchasing an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd acquired a new position in shares of Nuvalent in the 3rd quarter valued at about $38,000. NBC Securities Inc. acquired a new position in shares of Nuvalent in the 4th quarter valued at about $125,000. Finally, KBC Group NV lifted its stake in shares of Nuvalent by 24.1% in the 4th quarter. KBC Group NV now owns 1,527 shares of the company’s stock valued at $154,000 after purchasing an additional 297 shares in the last quarter. 97.26% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Positive Sentiment: GSK agreed to buy Nuvalent for $10.6 billion in cash, paying $124.00 per share and giving shareholders a large premium versus pre-deal trading levels. Reuters article
• Positive Sentiment: The acquisition gives Nuvalent investors a clear cash exit and reduces the uncertainty tied to clinical-stage biotech development, which has helped drive the stock near its takeover value. WSJ article
• Neutral Sentiment: Several analysts responded to the announcement by adjusting ratings and price targets to around the deal price, signaling that upside is now largely tied to merger completion rather than standalone fundamentals. Analyst update article
• Negative Sentiment: Law firms including Kahn Swick & Foti, Ademi LLP, and others are investigating whether the sale process and $124.00-per-share price are fair to shareholders, which could add noise and legal overhang to the deal. Business Wire article

Nuvalent Company Profile

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.